Optimizing the Diagnosis and Management of Spasticity: Methods for Improving Care Post Stroke, Post-TBI, and in Children with Cerebral Palsy

Jointly provided by

Supported by an educational grant from Ipsen Biopharmaceuticals, Inc.

Effective treatment of patients with spasticity as a result of upper motor neuron syndrome due to stroke, traumatic brain injury, and cerebral palsy (CP) begins with early, accurate assessment. Treatment can be multifaceted, involving chemodenervation, systemic medications, surgical therapy, rehabilitation efforts, and home care. These interactive video activities will address caring for and managing patients with these conditions; Module 1 will focus on assessing pediatric and adult patients’ spasticity and functional consequences; Module 2 will review various treatment options for pediatric and adult patients with spasticity; and Module 3 will address techniques in developing customized treatment options for various patient types based on their diagnosis and treatment goals.

Each module offers:

  • 0.5 AMA PRA Category 1 Credit&trade for physicians, per module

This activity has been planned and implemented by Dannemiller and ASiM. In support of improving patient care, Dannemiller is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Module 1 – Assessing Spasticity and Functional Consequences

In this roundtable discussion, the clinical evaluation of adult and pediatric patients with  spasticity is discussed, including the relationship between spasticity and contracture, active and passive function, quality of life, and the use of various assessment scales. In addition, the progressive nature of CP’s manifestations and the resulting impacts on function over a lifetime are considered.


Module 2 – Treatment Options for Spasticity

While botulinum toxin plays a major role in providing patients with symptomatic relief from hypertonia, often resulting with improvements in function, it should rarely be a stand-alone treatment. This roundtable discussion will address the role of all currently available treatments for pediatric and adult patients with spasticity and how best to achieve optimal care.


Module 3 – Individualized Management

In this roundtable discussion, clinical experts address the importance of patient assessment and treatment options highlighting the need for individualized management. Emphasis is placed on setting appropriate, customized goals for each patient and using these goals to determine treatment decisions. Treatment options are then discussed in more detail, including optimal use of botulinum toxin.